Systematic review and meta-analysis comparing the autogenous vein bypass versus a prosthetic graft for above-the-knee femoropopliteal bypass surgery in patients with intermittent claudication

医学 外科 间歇性跛行 严重肢体缺血 跛行 临床终点 人口 随机对照试验 大隐静脉 静脉 血管疾病 动脉疾病 环境卫生
作者
Rianne Vossen,TM Fokkema,A.C. Vahl,Ron Balm
出处
期刊:Vascular [SAGE Publishing]
卷期号:: 170853812211247-170853812211247 被引量:3
标识
DOI:10.1177/17085381221124701
摘要

According to guidelines, the autogenous saphenous vein (ASV) is the preferred conduit for femoropopliteal bypass surgery in all patients with peripheral artery disease. However, in contrast to patients with critical limb ischemia (CLI), patients with intermittent claudication (IC) only, tend to have milder disease, and thus a prosthetic graft may be as good as a vein conduit. The objective of this study was to compare patency rates of the ASV and a prosthetic graft in femoropopliteal bypass surgery in patients with IC.A systematic literature search was performed in the PubMed, Embase, and Cochrane databases to identify randomized controlled trials comparing prosthetic graft versus ASV in patients with IC. Articles with a mixed IC and CLI study population were included if more than 50% of the study cohort was treated for IC. Primary analysis was performed on IC patients only. Secondary analysis was performed on the mixed group. The primary endpoint was short- and long-term patency and secondary endpoints were complications, limb salvage, and mortality.In total, six studies with 524 patients were included. Only two studies reported solely on patients with IC. All these patients underwent above-the-knee bypasses and average patency rates at one and 5 years were 88% and 76% vs 81% and 68% in the ASV and the PTFE groups, respectively. One and five-year patency was not statistically different between the groups (OR 5.21; 95% CI 0.60-45.36 and OR 2.10; 95% CI 0.88-5.01). In a mixed population of patients with IC and CLI (84% IC patients), 1 year patency was comparable (OR 1.40; 95% CI 0.87-2.25). However, after a follow-up of over 3 years, this mixed group had significantly higher patency rates in favour of the ASV (OR 2.06; 95 % CI 1.30-3.26). Complication and amputation rates were comparable in both groups.Limited data are available for patients receiving above-the-knee femoropopliteal bypass for intermittent claudication. The ASV remains the conduit of choice for femoropopliteal bypass surgery. However, the prosthetic conduit seems a feasible alternative for patients with intermittent claudication in whom the ASV is not present or unsuitable.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
达达发布了新的文献求助10
刚刚
无花果应助成就小蜜蜂采纳,获得10
刚刚
Sun1314完成签到,获得积分10
2秒前
辛勤牛青完成签到,获得积分20
3秒前
4秒前
阿羡完成签到 ,获得积分10
4秒前
5秒前
157发布了新的文献求助10
5秒前
wuyu发布了新的文献求助10
5秒前
心想事成完成签到,获得积分10
6秒前
7秒前
7秒前
CodeCraft应助zhouyi采纳,获得10
7秒前
烟花应助满意代亦采纳,获得10
8秒前
9秒前
酷波er应助liliy采纳,获得10
9秒前
薛南南发布了新的文献求助10
9秒前
MUXIYOU完成签到,获得积分10
10秒前
天天快乐应助小白采纳,获得10
11秒前
Rsoup发布了新的文献求助10
12秒前
染唔唔发布了新的文献求助10
13秒前
xxy发布了新的文献求助10
14秒前
科研通AI2S应助辛勤牛青采纳,获得10
17秒前
Desirable完成签到,获得积分10
19秒前
21秒前
21秒前
22秒前
蓝天发布了新的文献求助10
23秒前
深情安青应助我是CF大王采纳,获得10
24秒前
秋秋完成签到 ,获得积分10
24秒前
Elias完成签到 ,获得积分10
24秒前
陈东东完成签到,获得积分10
25秒前
染唔唔完成签到,获得积分10
28秒前
单薄的蛋挞完成签到,获得积分10
28秒前
三分发布了新的文献求助10
28秒前
28秒前
29秒前
30秒前
星星发布了新的文献求助10
31秒前
32秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
PowerCascade: A Synthetic Dataset for Cascading Failure Analysis in Power Systems 2000
Picture this! Including first nations fiction picture books in school library collections 1500
Instituting Science: The Cultural Production of Scientific Disciplines 666
Signals, Systems, and Signal Processing 610
The Organization of knowledge in modern America, 1860-1920 / 600
Unlocking Chemical Thinking: Reimagining Chemistry Teaching and Learning 555
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6360875
求助须知:如何正确求助?哪些是违规求助? 8174791
关于积分的说明 17219733
捐赠科研通 5415946
什么是DOI,文献DOI怎么找? 2866077
邀请新用户注册赠送积分活动 1843305
关于科研通互助平台的介绍 1691363